In Vitro Effect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells

References

• Hartmann C, Bostrom J, Simon M. Diagnostic and molecular pathology of meningiomas. Expert Rev Neurother. 2006;6(11):1671–1683. doi:10.1586/14737175.6.11.1671.
   PubMedGoogle Scholar
• Miller R, Jr, DeCandio ML, Dixon-Mah Y, Giglio P, Vandergrift WA, 3rd, Banik NL, et al. Molecular targets and treatment of meningioma. J Neurol Neurosurg. 2014;01(01):1000101. doi:10.19104/jnn.2014.101.
   Google Scholar
• Hanft S, Canoll P, Bruce JN. A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol. 2010;99(3):433–443. doi:10.1007/s11060-010-0348-9.
   PubMed Web of Science ®Google Scholar
• Herbst A, Mueller-Vogt U, Brawanski A, Proescholdt M, Riemenschneider MJ, Schebesch KM. WHO grade III anaplastic meningioma metastasizing to the parotid gland and the lungs: case report and review of the literature. J Neurol Surg A Cent Eur Neurosurg. 2013;74(3):197–202. doi:10.1055/s-0032-1313722.
   PubMedGoogle Scholar
• Yang HW, Kim TM, Song SS, Shrinath N, Park R, Kalamarides M, et al. Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma. Neoplasia. 2012;14(1):20–28. doi:10.1593/neo.111574.
   PubMed Web of Science ®Google Scholar
• Ragel BT, Jensen RL. Molecular genetics of meningiomas. Neurosurg Focus. 2005;19(5):E9. doi:10.3171/foc.2005.19.5.10.
   PubMedGoogle Scholar
• Sharma M, Schilero C, Peereboom DM, Hobbs BP, Elson P, Stevens GHJ, et al. Phase II study of dovitinib in recurrent glioblastoma. J Neurooncol. 2019;144(2):359–368. doi:10.1007/s11060-019-03236-6.
   PubMed Web of Science ®Google Scholar
• Chiu YH, Lee YY, Huang KC, Liu CC, Lin CS. Dovitinib triggers apoptosis and autophagic cell death by targeting SHP-1/p-STAT3 signaling in human breast cancers. J Oncol. 2019;2019:2024648.
   PubMed Web of Science ®Google Scholar
• Kähkönen TE, Tuomela JM, Grönroos TJ, Halleen JM, Ivaska KK, Härkönen PL. Dovitinib dilactic acid reduces tumor growth and tumor-induced bone changes in an experimental breast cancer bone growth model. J Bone Oncol. 2019;16:100232. doi:10.1016/j.jbo.2019.100232.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Kim HS, Park SH, Kim BS, Kim KH, Lee HJ, et al. Phase II study of dovitinib in patients with castration-resistant prostate cancer (KCSG-GU11-05). Cancer Res Treat. 2018;50(4):1252–1259. doi:10.4143/crt.2017.438.
   PubMed Web of Science ®Google Scholar
• Semrad TJ, Kim EJ, Tanaka MS, Sands J, Roberts C, Burich RA, et al. Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy. Cancer Treat Res Commun. 2017;10:21–26. doi:10.1016/j.ctarc.2016.12.002.
   PubMedGoogle Scholar
• Das A, Alshareef M, Henderson F, Jr, Martinez Santos JL, Vandergrift WA, 3rd, Lindhorst SM, et al. Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth. Clin Transl Oncol.2020;22:1138–1145. doi:10.1007/s12094-019-02240-6.
   PubMedGoogle Scholar
• Das A, Miller R, Lee P, Holden CA, Lindhorst SM, Jaboin J, et al. A novel component from citrus, ginger, and mushroom family exhibits antitumor activity on human meningioma cells through suppressing the Wnt/β-catenin signaling pathway. Tumour Biol. 2015;36(9):7027–7034. doi:10.1007/s13277-015-3388-0.
   PubMedGoogle Scholar
• Das A, Guyton MK, Smith A, Wallace G, 4th, McDowell ML, Matzelle DD, et al. Calpain inhibitor attenuated optic nerve damage in acute optic neuritis in rats. J Neurochem. 2013;124(1):133–146. doi:10.1111/jnc.12064.
   PubMed Web of Science ®Google Scholar
• Brands RC, Knierim LM, De Donno F, Steinacker V, Hartmann S, Seher A, et al. Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro. Oncol Rep. 2017;38(3):1877–1885. doi:10.3892/or.2017.5801.
   PubMed Web of Science ®Google Scholar
• Baek SW, Seo YJ, Lee HJ. Multiple milia associated with use of the tyrosine kinase inhibitor dovitinib. Australas J Dermatol. 2018;59(1):57–58. doi:10.1111/ajd.12620.
   PubMed Web of Science ®Google Scholar
• Johnson MD, O’Connell MJ, Pilcher W, Reeder JE. Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway. J Neurosurg. 2010;112(5):934–939. doi:10.3171/2009.7.JNS09726.
   PubMed Web of Science ®Google Scholar
• Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, et al. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol. 2015;16(6):686–694. doi:10.1016/S1470-2045(15)70159-2.
   PubMed Web of Science ®Google Scholar
• Lim SH, Sun JM, Choi YL, Kim HR, Ahn S, Lee JY, et al. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: a single-arm, phase 2 study. Cancer. 2016;122(19):3024–3031. doi:10.1002/cncr.30135.
   PubMed Web of Science ®Google Scholar
• Langdon CG, Held MA, Platt JT, Meeth K, Iyidogan P, Mamillapalli R, et al. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors. Pigment Cell Melanoma Res. 2015;28(4):417–430. doi:10.1111/pcmr.12376.
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215–266. doi:10.1002/wdev.176.
   PubMed Web of Science ®Google Scholar